Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Peripheral T-Cell Lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1973-1978, 2019.
Article
de Zh
| WPRIM
| ID: wpr-781509
Bibliothèque responsable:
WPRO
ABSTRACT
OBJECTIVE@#To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).@*METHODS@#The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep. 2018 in the department of hematology, aerospace center hospital were retrospectively analyzed. Complications and disease-free survival after HSCT were observed.@*RESULTS@#All the patients could well tolerate the conditioning regimen and acquired hematopoietic recon-struction. Following up till December 2018, with a median time of 11.5 months (1-51); acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases, Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival. The longest disease-free survival time has reached 51 months.@*CONCLUSION@#allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-cell lymphoma, which can be chosen as salvage treatment method for patients with primary resistance. Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Thérapeutique
/
Transplantation homologue
/
Études rétrospectives
/
Lymphome T périphérique
/
Transplantation de cellules souches hématopoïétiques
/
Conditionnement pour greffe
/
Maladie du greffon contre l'hôte
Type d'étude:
Observational_studies
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2019
Type:
Article